Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKlinkenberg-Knol, E.en
dc.contributor.authorNelis, F.en
dc.contributor.authorDent, J.en
dc.contributor.authorSnel, P.en
dc.contributor.authorMitchell, B.en
dc.contributor.authorPrichard, P.en
dc.contributor.authorLloyd, D.en
dc.contributor.authorHavu, N.en
dc.contributor.authorFrame, M.en
dc.contributor.authorRoman, J.en
dc.contributor.authorWalan, A.en
dc.identifier.citationGastroenterology, 2000; 118(4):661-669en
dc.description.abstractBACKGROUND & AIMS:The efficacy and safety of long-term acid suppression remains a subject for debate. We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6.5 years (range, 1.4-11.2 years). METHODS:Patients with severe reflux esophagitis resistant to long-term therapy with H(2)-receptor antagonists and who were not eligible for surgery were evaluated at least annually for endoscopic relapse and histological changes in the gastric corpus. RESULTS:In 230 patients (mean age, 63 years at entry; 36% were >/=70 years), there were 158 relapses of esophagitis during 1490 treatment years (1 per 9.4 years), with no significant difference in relapse rates between Helicobacter pylori-positive and -negative patients. All patients rehealed during continued therapy with omeprazole at the same or higher dose. The annual incidence of gastric corpus mucosal atrophy was 4.7% and 0.7% in H. pylori-positive and -negative patients, respectively, which was mainly observed in elderly patients who had moderate/severe gastritis at entry. In patients with baseline moderate/severe gastritis, the incidences were similar: 7.9% and 8.4%, respectively. Corpus intestinal metaplasia was rare, and no dysplasia or neoplasms were observed. The adverse event profile was as might be expected from this elderly group of patients. CONCLUSIONS:Long-term omeprazole therapy (up to 11 years) is highly effective and safe for control of reflux esophagitis.en
dc.publisherW B Saunders Coen
dc.subjectLong-Term Study Group; Gastric Mucosa; Humans; Helicobacter Infections; Barrett Esophagus; Gastroesophageal Reflux; Esophagitis; Gastritis; Hyperplasia; Omeprazole; Gastrins; Anti-Ulcer Agents; Treatment Outcome; Drug Resistance; Time Factors; Adolescent; Adult; Aged; Aged, 80 and over; Middle Aged; Child; Female; Maleen
dc.titleLong-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosaen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.